Rush University Medical Center

Other

Kalipada Pahan

Avik Roy

Arunava Ghosh

This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of a neurodegenerative disorder or glycine encephalopathy. The pharmaceutical compositions may include cinnamic acid. The pharmaceutical compositions and formulations may be orally administered to the patient.

Compositions including cinnamic acid and methods of use thereof

Provided herein are methods for delivering acetylsalicylic acid via nasal delivery for the treatment of neurodegenerative and lysosomal storage disorders, such as Alzheimer's disease and Batten disease.

Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases

Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.

Compositions and methods for treating neurological and other disorders

The present invention generally relates to compositions and methods for treating a neurological disorder in a subject, the method including administering to the subject in need of such treatment a composition including a therapeutically effective amount of a CCR5 antagonist. The CCR5 antagonist may be, for example, maraviroc. The neurological disorder may be, for example, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies or multiple system atrophy.

Compositions and methods for treating neurological disorders

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

Compositions and methods for treating lysosomal disorders

The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-β protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor α ('PPARα') to a human or veterinary subject in need of such treatment.

Composition and methods for stimulating clearance of amyloid-beta protein

Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

Peptides for the treatment of COVID-19

Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP1.

Composition and method for treating neuronal ceroid lipofuscinosis

Methods of modulating peroxisome proliferator-activated receptor &#x3b1; (PPAR&#x3b1;) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR&#x3b1; ligand to the subject where the PPAR&#x3b1; ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT). Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR&#x3b1; ligand to the subject.

Brain derived PPAR&#x3b1; ligands

Peptides for the treatment of covid-19

This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.

Use of a benzoate containing composition to treat glycine encephalopathy

One aspect of the invention provides a method for treating a cancer including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an antibody directed against p40 monomer or an immunologically active fragment thereof. In various embodiments, the antibody is a polyclonal, monoclonal, human, humanized, and chimeric antibody; a single chain antibody or an epitope-binding antibody fragment. In other embodiments, the cancer is, for example, prostate cancer, breast cancer or liver cancer.

Compositions and methods for treating cancer

The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-&#x3b2; protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor a ('PPAR&#x3b1;') to a human or veterinary subject in need of such treatment.

Growing community of inventors

Skokie, IL, United States of America

Kalipada Pahan